Lara Bonner Millar, MD
Radiation Oncology · Norfolk, VANPI 1336354745
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,000 of the $6,216 with a category attached, or 64.4%. Novocure Inc. accounts for 81.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $5,203 and has fallen 89.5% since, to $544 in 2024. Among radiation oncology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 16 payments — averaging $388.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$5K
- AstraZeneca$648
- Merck$124
- Myriad Genetic Laboratories, Inc.$119
- AbbVie$107
- GSK$100
- plus $85 from 1 others
What the payments were for
- Consulting fees$62510%
- Speaking & faculty fees$4,00064%
- Travel & lodging$71612%
- Food & beverage$87414%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 9 | $5,032 |
| AstraZeneca | 2 | $648 |
| Merck | 1 | $124 |
| Myriad Genetic Laboratories, Inc. | 1 | $119 |
| AbbVie | 1 | $107 |
| GSK | 1 | $100 |
| Seagen Inc. | 1 | $85 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,216 in reported general payments places this provider in the 90th percentile of 121 radiation oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 19 | $100 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Norfolk
- Jacob HallNorfolk$4K
- Edwin CrandleyNorfolk$1K
- Scott WilliamsNorfolk$871
- David RandolphNorfolk$580
- Heather JonesNorfolk$445
- Mark ShavesNorfolk$419
- Daniel KimFairfax$406K
- Samir KananiFairfax$90K
- David PenberthyCharlottesville$67K
- Gopal BajajFairfax$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.